Related references
Note: Only part of the references are listed.Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer
Qian Zhou et al.
EMBO MOLECULAR MEDICINE (2022)
Novel fabrication of marizomib-loaded chitosan-coated hydroxyapatite nanocarriers as a promising system for effective treatment of ovarian cancer
Jia Xu et al.
MATERIALS RESEARCH EXPRESS (2022)
Site-Specific Proteasome Inhibitors
Alexei F. Kisselev
BIOMOLECULES (2022)
Targeting Proteasomes in Cancer and Infectious Disease: A Parallel Strategy to Treat Malignancies and Microbes
James J. Ignatz-Hoover et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)
Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed/refractory acute lymphoblastic leukemia
Michael J. Burke et al.
PEDIATRIC BLOOD & CANCER (2022)
Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo
Ziruizhuo Zhang et al.
FRONTIERS IN ONCOLOGY (2022)
PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer
Xueyan Wang et al.
CELL REPORTS MEDICINE (2022)
Beyond K48 and K63: non-canonical protein ubiquitination
Michal Tracz et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2021)
Protein degradation control and regulation of bacterial survival and pathogenicity: the role of protein degradation systems in bacteria
Shilei Dong et al.
MOLECULAR BIOLOGY REPORTS (2021)
Proteasome inhibitor MG132 induces apoptosis in human osteosarcoma U2OS cells
Han Ki Lee et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2021)
Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy
Fatemeh Aliabadi et al.
OPEN BIOLOGY (2021)
Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells
Kazuki Okubo et al.
ANTICANCER RESEARCH (2021)
Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist
Chiara Boccellato et al.
CELL DEATH & DISEASE (2021)
Modulation of Tumor Microenvironment to Enhance Radiotherapy Efficacy in Esophageal Squamous Cell Carcinoma by Inhibiting Carbonic Anhydrase IX
Pengqin Xu et al.
FRONTIERS IN ONCOLOGY (2021)
Advancing targeted protein degradation for cancer therapy
Brandon Dale et al.
NATURE REVIEWS CANCER (2021)
Proteasome Inhibitor Drugs
Lloyd D. Fricker
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells
Jessica L. Rausch et al.
SCIENTIFIC REPORTS (2020)
The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms
Francesca Felicia Caputi et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Proteasome Inhibitor MG132 is Toxic and Inhibits the Proliferation of Rat Neural Stem Cells but Increases BDNF Expression to Protect Neurons
Young Min Kim et al.
BIOMOLECULES (2020)
Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
Prahlad Raninga et al.
THERANOSTICS (2020)
Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation
Xuesen Li et al.
CELL COMMUNICATION AND SIGNALING (2019)
A Practical Review of Proteasome Pharmacology
Tiffany A. Thibaudeau et al.
PHARMACOLOGICAL REVIEWS (2019)
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis
Mopei Wang et al.
THORACIC CANCER (2019)
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Pawel Robak et al.
DRUGS IN R&D (2019)
EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
P. Roth et al.
NEURO-ONCOLOGY (2019)
Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells
Dan Yue et al.
CANCER BIOLOGY & THERAPY (2019)
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis
Matthew Ho Zhi Guang et al.
CANCERS (2019)
An oral second-generation proteasome inhibitor oprozomib significantly inhibits lung cancer in a p53 independent manner in vitro
Hongge Zhu et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2019)
New proteasome inhibitors in the treatment of multiple myeloma
Vania Tietsche de Moraes Hungria et al.
HEMATOLOGY TRANSFUSION AND CELL THERAPY (2019)
Proteasome Inhibitor Carfilzomib Enhances the Anticancer Effect of Paclitaxel in MDA-MB-231 Breast Cancer Cells
Hatice Terzi et al.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
Wei Liu et al.
ONCOTARGET (2018)
Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells
Makoto Isono et al.
ANTICANCER RESEARCH (2018)
MP72-09 RITONAVIR AND IXAZOMIB INHIBIT RENAL CANCER GROWTH IN VITRO AND IN VIVO BY INDUCING ENDOPLASMIC RETICULUM STRESS SYNERGISTICALLY
Takako Asano et al.
JOURNAL OF UROLOGY (2018)
A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17 beta-estradiol: ER alpha signaling and cell proliferation in breast cancer cells
Claudia Busonero et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2018)
Next-generation proteasome inhibitors for cancer therapy
Ji Eun Park et al.
TRANSLATIONAL RESEARCH (2018)
Oncogenic addiction to high 26S proteasome level
Peter Tsvetkov et al.
CELL DEATH & DISEASE (2018)
Structure and Function of the 26S Proteasome
Jared A. M. Bard et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 87 (2018)
Regulation of proteasome assembly and activity in health and disease
Adrien Rousseau et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Regulation of Protein Degradation by Proteasomes in Cancer
Ho Hee Jang
JOURNAL OF CANCER PREVENTION (2018)
Positioning of proteasome inhibitors in therapy of solid malignancies
Margot S. F. Roeten et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study
Xue-feng Yang et al.
ONCOTARGET (2017)
Proteasome Structure and Assembly
Lauren Budenholzer et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma
Dan T. Vogl et al.
LEUKEMIA & LYMPHOMA (2017)
Proteasome inhibitors in cancer therapy
Elisabet E. Manasanch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Proteasome expression and activity in cancer and cancer stem cells
Ioannis A. Voutsadakis
TUMOR BIOLOGY (2017)
Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway
Kevin Y. Guo et al.
ONCOTARGET (2017)
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review
Nicolas Kerckhove et al.
FRONTIERS IN PHARMACOLOGY (2017)
Redox regulation of proteasome function
Maria Lefaki et al.
REDOX BIOLOGY (2017)
Proteasome Inhibitor MG132 Enhances Sensitivity to Cisplatin on Ovarian Carcinoma Cells In Vitro and In Vivo
Na Guo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design
Jil Schrader et al.
SCIENCE (2016)
Spotlight on ixazomib: potential in the treatment of multiple myeloma
Barbara Muz et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma
Yves-Paul Vandewynckel et al.
ONCOTARGET (2016)
The combination of MLN2238 (Ixazomib) with interferon-alpha results in enhanced cell death in melanoma
Lorena P. Suarez-Kelly et al.
ONCOTARGET (2016)
Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells
Yonghua Shi et al.
ONCOTARGET (2016)
Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis
Shan Guan et al.
ONCOTARGET (2016)
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma
Meirong Zang et al.
CANCER LETTERS (2015)
Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer
Amit Mehta et al.
ENDOCRINE-RELATED CANCER (2015)
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism
Nibedita Chattopadhyay et al.
PLOS ONE (2015)
Targeted treatments for multiple myeloma: specific role of carfilzomib
Dhivya Sugumar et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2015)
Regulation of proteasome activity in health and disease
Marion Schmidt et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
Raymond J. Deshaies
BMC BIOLOGY (2014)
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors
Yan Zang et al.
CANCER BIOLOGY & THERAPY (2014)
Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Q. Ping Dou et al.
CURRENT CANCER DRUG TARGETS (2014)
Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo
Weiwei Tang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
Amanda F. Baker et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model
Izabela Mlynarczuk-Bialy et al.
Translational Oncology (2014)
MG132, a proteasome inhibitor, induces apoptosis in tumor cells
Na Guo et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2013)
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
Elisa Gallerani et al.
EUROPEAN JOURNAL OF CANCER (2013)
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
M. A. Hurchla et al.
LEUKEMIA (2013)
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes
Kyung Bo Kim et al.
NATURAL PRODUCT REPORTS (2013)
The resistance mechanisms of proteasome inhibitor bortezomib
Shuqing Lu et al.
BIOMARKER RESEARCH (2013)
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4
Yan Zang et al.
AUTOPHAGY (2012)
Covalent and non-covalent reversible proteasome inhibition
Philipp Beck et al.
BIOLOGICAL CHEMISTRY (2012)
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Alexei F. Kisselev et al.
CHEMISTRY & BIOLOGY (2012)
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
Michael Millward et al.
INVESTIGATIONAL NEW DRUGS (2012)
Development of proteasome inhibitors as research tools and cancer drugs
Alfred L. Goldberg
JOURNAL OF CELL BIOLOGY (2012)
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma
Eric Sanchez et al.
LEUKEMIA RESEARCH (2012)
MG132, a proteasome inhibitor, induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion
Woo Hyun Park et al.
ONCOLOGY REPORTS (2012)
Elucidation of the alpha-Keto-Aldehyde Binding Mechanism: A Lead Structure Motif for Proteasome Inhibition
Melissa Ann Graewert et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
Teru Hideshima et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Up-regulation of the DR5 Expression by Proteasome Inhibitor MG132 Augments TRAIL-Induced Apoptosis in Soft Tissue Sarcoma Cell Lines
Hee-Jeong Cheong et al.
CANCER RESEARCH AND TREATMENT (2011)
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies
N. Reddy et al.
ANNALS OF ONCOLOGY (2010)
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-κB Activity
Yoichi Matsuo et al.
DIGESTIVE DISEASES AND SCIENCES (2010)
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma
Jan Sterz et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Snapshots of the Fluorosalinosporamide/20S Complex Offer Mechanistic Insights for Fine Tuning Proteasome Inhibition
Michael Groll et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia
Jacob P. Laubach et al.
LEUKEMIA & LYMPHOMA (2009)
The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH
Yong Hwan Han et al.
ONCOLOGY REPORTS (2009)
Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp
Yafei Zhang et al.
CANCER BIOLOGY & THERAPY (2008)
Mechanism of gate opening in the 20S proteasome by the proteasomal ATPases
Julius Rabl et al.
MOLECULAR CELL (2008)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Roberto Piva et al.
BLOOD (2008)
The Proteasome Inhibitor MG132 Sensitizes Lung Cancer Cells to TRAIL-induced Apoptosis by Inhibiting NF-k B Activation
Pil Won Seo et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2008)
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy
A. L. Goldberg
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
20S proteasome and its inhibitors: Crystallographic knowledge for drug development
Ljudmila Borissenko et al.
CHEMICAL REVIEWS (2007)
Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells
Izabela Mlynarczuk-Bialy et al.
CANCER RESEARCH (2006)
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132
Lisa J. A. Crawford et al.
CANCER RESEARCH (2006)
Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies
G Jackson et al.
CANCER TREATMENT REVIEWS (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Salinispora arenicola gen. nov., sp nov and Salinispora tropica sp nov., obligate marine actinomycetes belonging to the family Micromonosporaceae
LA Maldonado et al.
INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY (2005)
Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines
HA Braun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells
M Duechler et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib
JC Cusack
CANCER TREATMENT REVIEWS (2003)
Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus Salinospora
RH Feling et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2003)
Proteasome inhibitors: from research tools to drug candidates
AF Kisselev et al.
CHEMISTRY & BIOLOGY (2001)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)
Share Paper
